Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Scinai Immunotherapeutics ( (SCNI) ) is now available.
On March 5, 2025, Scinai Immunotherapeutics announced a $10 million Standby Equity Purchase Agreement with Yorkville Advisors, allowing Scinai to sell its American Depository Shares over a three-year period. This agreement provides Scinai with financial flexibility to support its R&D and CDMO business expansion, enabling the company to strategically access capital as needed without mandatory commitments.
More about Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company that focuses on developing inflammation and immunology biological products. It operates two business units: one dedicated to creating nanosized VHH antibodies (nanoAbs) for diseases with significant unmet needs, and a boutique CDMO offering drug development and manufacturing services.
YTD Price Performance: -2.85%
Average Trading Volume: 12,267
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.85M
Learn more about SCNI stock on TipRanks’ Stock Analysis page.